JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
JOHNSON & JOHNSON
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
Share price
+$60.57 (+31.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
JOHNSON & JOHNSON grew revenue 8.1% to $97.93B over the twelve months to Jun 28, 2026. Free cash flow was $22.24B, up 19.9% from a year earlier.
Revenue
$97.93B
+8.1% vs. a year earlier
Free cash flow
$22.24B
+19.9% vs. a year earlier
EPS, diluted
$8.62
-7.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 28, 2026
Valuation
- Market cap
- $619.27B
- P/E ratio
- 29.4
- Price to sales
- 6.32
- Price to book
- 7.29
- Dividend yield
- 2.03%
- Free cash flow yield
- 3.59%
Fundamentals
- Revenue
- $97.93B
- Net income
- $21.04B
- EPS, diluted
- $8.62
- Free cash flow
- $22.24B
- Book value per share
- $34.82
- Diluted shares
- 2.44B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$97.93B+8.1% YoY
Gross profit
$66.50B+8.0% YoY
Operating income
–
Net income
$21.04B-7.2% YoY
EPS, diluted
$8.62-7.8% YoY
Free cash flow
$22.24B+19.9% YoY
Reported periodTrailing twelve months